Recommendation and Guideline
- Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association
-
Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim
-
J Liver Cancer. 2023;23(2):241-261. Published online July 14, 2023
-
DOI: https://doi.org/10.17998/jlc.2023.05.22
-
-
2,332
Views
-
148
Downloads
-
4
Citations
-
Abstract
PDF
- Transarterial chemoembolization (TACE) was introduced in 1977 with the administration of chemotherapeutic agent to gelatin sponge particles through the hepatic artery in patients with hepatocellular carcinoma (HCC) and was established as conventional TACE using Lipiodol in the 1980s. In the 2000s, drug-eluting beads were developed and applied clinically. Currently, TACE is a commonly used non-surgical treatment modality for patients with HCC who are unsuitable for curative treatment. Considering the vital role of TACE in the management of HCC, it is crucial to organize current knowledge and expert opinions regarding patient preparation, procedural techniques, and post-treatment care in TACE, which can enhance therapeutic efficacy and safety. A group of 12 experts in the fields of interventional radiology and hepatology, convened by the Research Committee of the Korean Liver Cancer Association (KLCA), has developed expert consensus-based practical recommendations in TACE. These recommendations have been endorsed by the Korean Society of Interventional Radiology and provide useful information and direction in performing TACE procedure as well as pre- and post- procedural patient care.
-
Citations
Citations to this article as recorded by
- Liver resection in selective hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombosis improves prognosis
Manuel Lim, Jongman Kim, Jinsoo Rhu, Gyu-Seong Choi, Jae-Won Joh
Journal of Liver Cancer.2024; 24(1): 102. CrossRef - A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization
Hae Lim Lee, Seok Hwan Kim, Hee Yeon Kim, Sung Won Lee, Myeong Jun Song
Frontiers in Oncology.2024;[Epub] CrossRef - Clinical outcomes of transarterial chemoembolization in Child–Turcotte Pugh class A patients with a single small (≤3 cm) hepatocellular carcinoma
Jungnam Lee, Young‐Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Jung Hwan Yu, Jin‐Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
Journal of Gastroenterology and Hepatology.2024;[Epub] CrossRef - Implications of the first edition of the Korean expert consensus-based practice recommendations for transarterial chemoembolization in the management of hepatocellular carcinoma
Jin Wook Chung
Journal of Liver Cancer.2023; 23(2): 235. CrossRef
Original Article
- Epidemiologic Changes in Hepatocellular Carcinoma: A 10-year Single Center Experience in Gangneung, Korea
-
Young Don Kim, Woo Sung Jang, Jang Hoon Kwon, Jong Sam Hong, Gab Jin Cheon
-
Journal of the Korean Liver Cancer Study Group. 2013;13(2):123-129. Published online September 30, 2013
-
DOI: https://doi.org/10.17998/jlc.13.2.123
-
-
Abstract
PDF
- Background/Aims
Hepatocellular carcinoma (HCC) is common cause of liver related death in Korea, and the importance of alcohol as an etiology of chronic liver disease including cirrhosis is emphasized recently. We investigated the epidemiologic changes of HCC during last 10 years in single tertiary center in Gangneung, Korea.
Methods
We retrospectively reviewed the medical records of admitted patients diagnosed as HCC in year 2002 and 2012 respectively, and their clinical characteristics were compared.
Results
A total of 214 patients were enrolled. Mean age was 60.1 years and 179 (83.6%) was male. Number of patient with cirrhosis was 160 (74.8%) and with viral hepatitis was 164 (74.8%). Chronic hepatitis B (CHB) was the most common cause of HCC patients with liver cirrhosis (61.9%), and alcohol was 14.4%. The possible curative group (by BCLC stage 0 or A) was only 36.4% (n=78), and had not decreased during the study periods (36.3 % vs. 36.6%, P=0.144), and other clinical variables also had no statistical differences.
Conclusions
The clinical characteristics of HCC including clinical stage at the time of diagnosis were not changed over the last 10 year period, and CHB was still the most common etiology of HCC in Gangneung, Korea.